Genzyme, the U.S. biotech unit of French drugmaker Sanofi SA (SASY.PA), failed to ship rare disease drug Fabrazyme in August despite telling doctors and patients the shipment would be prompt. U.S. drug regulators made public on Wednesday letters from Genzyme dated Aug. 25 and 26 in which the company apologized to healthcare providers and Fabry disease sufferers for "any confusion and disruption" caused by the delay. The regulators also released letters dated July 25 and 26 promising to ship the August allocations on time.
